Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France

Prior treatment

• Patients for whom AI or fulvestrant in monotherapy has been initiated \> 28 days before inclusion.
• Participation in any clinical study involving investigational therapy except for the Trans-RosaLEE study, conducted by the IPC.

Other

• Patients for whom ribociclib + AI in treatment combination has been initiated before inclusion.
• Patients for whom ribociclib + fulvestrant in treatment combination has been initiated before inclusion.
• Patient who is pregnant or has expressed desire for pregnancy during Ribociclib treatment.

• Patients who meet all of the following criteria will be included in the RosaLEE study:
• Adult women aged ≥ 18 years old at inclusion.
• Pre-/Peri-/Postmenopausal women with locally advanced or metastatic HR+/HER2- BC.
• Prior clinical decision (independent of study participation)to initiate ribociclib + ET treatment according to the marketing authorization.
• Patients having given their non-objection to participate in the study.
• Patients presenting with medical conditions to be treated with ribociclib + ET according to the summary of product characteristics.